BioPharma Dive1d
Biotech investors, including Third Rock, pump $100M into a startup’s genetic medicine for ALS
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...
Business Wire1d
Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Trace Neuroscience Launches with $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases, ...
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
FierceBiotech1d
Third Rock-backed Trace uses $101M series A to go after same ALS target as Lilly
Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.
STAT2d
Fueled by a ‘fall off your chair’ discovery and $101 million, Trace launches to take on ALS
Trace Neuroscience launched on Tuesday to announce that it is developing a genetic treatment targeting UNC13A, a gene linked ...
precisionmedicineonline2d
Neurogene Dropping Batten Disease Gene Therapy; Discloses Adverse Event in Rett Syndrome Trial
NEW YORK – Neurogene on Monday said after the market closed that it will stop advancing NGN-101 as a treatment for CLN5 Batten disease, a very rare genetic disorder. The New York-based company said it ...
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...
Beam Therapeutics’ Promising Genetic Medicines and Strategic Advancements Justify Buy Rating
H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on BEAM stock, giving a Buy rating today. Patrick Trucchio has ...